323 results about "Stent implantation" patented technology

Techniques and devices for treating atherosclerotic disease use controlled cryogenic cooling, often in combination with angioplasty and/or stenting. A combination cryogenic/angioplasty catheter may cool the diseased blood vessel before, during, and/or after dilation. Controlled cooling of the vessel wall reduces actual/observed hyperplasia as compared to conventional uncooled angioplasty. Similar reductions in restenosis may be provided for other primary treatments of the blood vessel, including directional arthrectomy, rotational arthrectomy, laser angioplasty, stenting, and the like. Cooling of vessel wall tissues will often be performed through plaque, and the cooling process will preferably take the thermodynamic effects of the plaque into account.

The stent with an outer slough coating 125 of the present invention provides a coated stent having a permanent coating 130 disposed on the stent and a slough coating 125 disposed on the permanent coating 130. The permanent coating 130 includes an anti-proliferative agent and the slough coating 125 includes an anti-inflammatory agent. The slough coating 125 erodes shortly after stent implantation to deliver the anti-inflammatory agent, which treats tissue trauma from the angioplasty and the presence of the stent. Once the slough coating 125 has substantially eroded, the permanent coating 130 delivers the anti-proliferative agent long-term to prevent tissue growth on the stent or within the body lumen, and prevent restenosis. The permanent coating 130 can also include an anti-inflammatory agent.

Methods and apparatus for direct coronary revascularization wherein a transmyocardial passageway is formed between a chamber of the heart and a coronary blood vessel to permit blood to flow therebetween. In some embodiments, the transmyocardial passageway is formed between a chamber of the heart and a coronary vein. The invention includes unstented transmyocardial passageways, as well as transmyocardial passageways wherein protrusive stent devices extend from the transmyocardial passageway into an adjacent coronary vessel or chamber of the heart. The apparatus of the present invention include protrusive stent devices for stenting of transmyocardial passageways, intraluminal valving devices for valving of transmyocardial passageways, intracardiac valving devices for valving of transmyocardial passageways, endogenous tissue valves for valving of transmyocardial passageways, and ancillary apparatus for use in conjunction therewith.

The method of vascular treatment for restenosis or vulnerable plaque after an invasive procedure, such as for example angioplasty, stenting with or without drug coating, or drug delivery, comprises: inserting a catheter or hollow guide wire to the treatment location; delivering light through the catheter in the wavelength range of about 700–2500 nm; and moving the light to treat the affected region.

Medical device and methods for delivery or implantation of prostheses within hollow body organs and vessels or other luminal anatomy are disclosed. The subject technologies may be used in the treatment of atherosclerosis in stenting procedures. For such purposes, a self-expanding stent may be deployed in connection with an angioplasty procedure with a sliding restraint based delivery system adapted for simplified use. In the system, the sliding restraint is sized, in coordination with a fixed sleeve accepting a core wire to actuate the restraint to effect an anchoring function with the sleeve so that the stent is not inadvertently advanced during deployment.

A method of stenting, comprises: implanting a stent assembly in a vessel of a subject, the stent assembly, including: a stent jacket, comprising an expansible mesh structure, formed of fibers of a diameter between about 7 micrometers and about 18 micrometers, the diameter having a property of forming a substantially stable layer of endothelial cells, covering the fibers, thus reducing platelet aggregation, and an expansible stent, operatively associated with the stent jacket. The method further comprises administering to the subject an active pharmaceutical ingredient (API) comprising a platelet aggregation reducer for a shortened time period, not exceeding six months, the shortened time period being a consequence of the property. In accordance with some embodiments, the administration of a platelet aggregation.

A permanent thrombus and plaque filtering stent blocks and/or filters potential emboli in patients undergoing intravascular treatment and/or stent implantation. The stent has a plurality of movable magnetic or ultrasonic agitating elements attached thereto, which when remotely activated move, vibrate or rotate to break up the thrombus, plaque or tissue debris.

An endoprosthesis comprising a stent, a cover fully covering the stent wherein the cover has variable porosity in the radial direction; and an adhesion layer connecting the stent to the cover. Another aspect of the invention is a method of implanting an endoprosthesis which includes a stent, providing a cover with variable porosity in the radial direction, connecting the stent to the cover with an adhesion layer to form a covered stent, and implanting the covered stent within a body lumen of a patient.

A stent pattern includes an improved portal region for repairing a main vessel and a side branch vessel forming a bifurcation. More particularly, the stent has rings aligned along a common longitudinal axis that are connected by links, where the stent has a proximal section, a distal section, and a central section (portal region). The number of rings and the expanded diameter of the sections are varied to create a “trap door” capable of expanding to a slightly larger diameter than the proximal section and the distal section of the stent. The configuration of the stent pattern of the portal region prevents the occurrence of portal overlap of immediately adjacent rings into the portal region during stent deployment. The stent is implanted at a bifurcation so that the proximal section and the distal section are in the main vessel, and the central section contacts at least a portion of the opening to the side branch vessel. A second stent can be implanted in the side branch vessel and abut the expanded central section to provide full coverage of the bifurcated area in the main vessel and the side branch vessel.

Medical device and methods for delivery or implantation of prostheses within hollow body organs and vessels or other luminal anatomy are disclosed. The subject technologies may be used in the treatment of atherosclerosis in stenting procedures. For such purposes, a self-expanding stent may be deployed in connection with an angioplasty procedure with a stent delivery system having a diameter adaptive restraint. Upon withdrawal of the restraint, the stent is freed, while the restraint or connections thereto assumes a reduced diameter within a tubular body of the delivery guide.

A unique design of the stent that incorporates a drug-reservoir running along the stent struts. One or more drugs can be incorporated within the reservoir. Additionally other drugs can be coated on the surface of the strut enclosing the reservoir drug to facilitate sequential release of drugs. Thus, the design incorporating sequential release of multiple drugs facilitates to tackle the sequential complex biologic processes involved in renarrowing following stent implantation. The design also ensures that the drug present in the reservoir is released exclusively into the adjacent tissue without getting washed away into the blood flowing within the lumen.

Disclosed is a focal balloon having at least one reference zone and a focal zone. In one embodiment, the reference zone and focal zone are inflatable to a first generally cylindrical profile at a first pressure. At a second, greater pressure, the focal section expands to a second, greater diameter, while the reference zone remains substantially at the first diameter. In an alternate embodiment, the focal zone and the reference zone are inflatable to their respective predetermined diameters at the inflation pressure, in the absence of constricting lesions or anatomical structures. Multiple lobed and drug delivery embodiments are also disclosed.

The present invention relates generally to medical devices containing nanoporous surfaces and methods for making same. More specifically, the invention relates to implantable vascular stents or other biomedical devices having at least one nanoporous layer that promotes improved cellular adhesion properties that promote healing and long term biocompatibility. In the case of stents, the nanoporous layer promotes re-endothelialization at sites of stent implantation vasculature, improves overall healing, and reduces inflammation and intimal disease progression. The nanoporous layer may be optionally loaded with one or more therapeutic agent to further improve the function of the implanted stent and further augment clinical efficacy.

Provided herein is an endothelial scaffold comprising, consisting of, or consisting essentially of decellularized corneal stroma. In some embodiments, the scaffold has cultured endothelial cells seeded thereon. Methods of treating a patient in need of corneal endothelial transplant are also provided, including implanting the scaffold as described herein onto a cornea of the patient (e.g., by deep keratectomy).

Disclosed herein are stents with degradable part and/or sections of the stent. The degradable portions of the disclosed stents can provide increased surface area for a period of time for bioactive material deposition or enhanced radiopacity at various locations along the length of the stent. The stents of the present invention also can stent portions of a vessel that are damaged by stent implantation but do not necessarily require long term stenting by providing degradable end sections on the stents of the present invention.

A bioresorbable endoluminal prosthesis for placement in a body lumen having a stent substrate of a first metallic material that has a lower electrical potential than a standard reference electrode. The stent substrate is coated with a biodegradable polymer having a second metallic material dispersed therein, wherein the second metallic material has a higher electrical potential than the standard reference electrode. After implantation of the stent within the body lumen, the second metallic material is present in the polymeric coating in a sufficient concentration to cause galvanic corrosion of the first metallic material such that over time the stent substrate is bioresorbed.

The present invention relates generally to a drug eluting stent containing metallic surfaces modified in microsphere metallic matrix structure and methods for making same. More specifically, the invention relates to an expandable and implantable vascular stent having at least one matrix layer that promotes improved cellular adhesion properties for healing promotion healing and long term biocompatibility. In the case of coronary stents, the metallic matrix layer promotes re-endothelialization at sites of stent implantation, improves overall healing, and reduces inflammation and intimal disease progression. The microsphere metallic matrix layer may be optionally loaded with one or more therapeutic agent to further improve the function of the implanted stent and further augment clinical efficacy and safety. The active compounds are selected primarily for their anti-proliferative, immunosuppressive, and anti-inflammatory activities, among other properties, which prevent, in part, smooth muscle cell proliferation and promote endothelial cell growth.

The invention discloses a left auricle plugging device and a transport system. The left auricle plugging device comprises a stent and a plugging device body. Firstly, the stent is implanted and fixed on the left auricle inlet position, the double-tray-shaped plugging device body is released on the stent for plugging a left auricle, and therefore the problem of cerebral apoplexy caused by left auricle thrombus because of atrial fibrillation can be solved. The left auricle plugging device is provided with the self-expandable nitinol stent, the stent is firmly fixed on the left auricle inlet position by depending on anchoring thorns, and then the appropriate plugging device body is released on the stent. The transport system transports the left auricle plugging device to the left auricle position. Compared with the prior art, the stent is firstly fixed on the left auricle inlet position, then the double-tray-shaped plugging device body is released on the stent, and therefore release accuracy and implanting stability of the plugging device body are improved, and the plugging device body has selectivity. After release, the stent and the the plugging device body can be recovered to a catheter for relocation or replacement.

Medical devices and methods for delivery or implantation of prostheses within hollow body organs and vessels or other luminal anatomy are disclosed. The subject technologies can be used in the treatment of atherosclerosis in stenting procedures or be used in variety of other procedures. The systems can employ a self expanding stent restrained by one or more members released by an electrolytically erodable latch.

The present invention tackles the challenging anatomic characteristics of the coronary artery disease in the bifurcation point and the origin of side-branch. The invention has a specifically designed angioplasty balloon catheter, particularly the balloon shape and profile, to be used in the diseased vessels at these difficult anatomic locations. In stent implanting into a coronary artery, a balloon catheter application is an inseparable requirement. A stent is a passive device that cannot be deployed in a diseased or stenosed artery without a pre-stent, with-stent and/or post-stent balloon dilatation. In majority (more than 95%) of available coronary stents, a stent is deployed by balloon expandable mode, meaning that the stent is delivered and expanded inside a vessel lumen by expanding a delivery balloon. This is done by crimping a stent over a folded balloon for delivery into a coronary artery. When expanded by balloon inflation, a stent is expanded and shaped passively by the inflated balloon shape and profile. The balloon catheter is designed to do angioplasty in the bifurcation and side-branch anatomy of coronary arteries, while minimizing the side effect. This specially designed balloon catheter is not only for balloon angioplasty dilatation of the bifurcation and side-branch anatomy, but is also for delivering and deploying specially designed bifurcation or side-branch stents into these difficult anatomic locations, as a stent delivery system.

Biocompatible coatings for medical devices are disclosed. Specifically, polymer coatings designed to control the release of bioactive agents from medical devices in vivo are disclosed. The present application also discloses providing vascular stents with controlled release coatings and related methods for making these coatings. Additional embodiments of the present invention include stents coated with the disclosed copolymer(s) and peptide drugs. Methods for treating or inhibiting post-stent implantation restenosis in patients are also provided.